Tumor cells acquire resistance to these compounds through multiple mechanisms, including a second-site mutation (T790M) in EGFR, amplification of MET or ERBB2, and conversion to a small cell lung cancer phenotype (Yu et al., 2013). The gene discussed is EGFR; the disease is neoplasm.